Fresenius Medical Care's Narrow Moat Reinforced by Margin Expansion Plans

Fresenius Medical Care treats patients with end-stage renal disease, or ESRD, primarily through its dialysis clinic network and related medical technology. Its strengths in these related areas help Fresenius maintain the leading global position in this market. Even with the threat of obesity drug expansion in the long run, we expect the firm to benefit from decent demand in developed markets, such as the US, and even faster expansion in emerging markets in the long run. With global ESRD patient growth expected to remain in the low to mid-single digits in the long run, with a slight increase per patient, we expect top-line growth for Fresenius to grow in the midsingle digits during the next five years. Additionally, the firm continues to boost its operating margins from a low base, which could positively influence its profit growth trajectory.